“All clear” isn’t always the end. Melanoma’s ability to recur months or years after surgery is shifting how clinicians think about treatment timelines. DDx host Raj Bhardwaj, MD, and Omid Hamid, MD, chief of translational research and immunotherapy at The Angeles Clinic and Research Institute in Los Angeles, explore strategies for identifying patients at high risk for melanoma recurrence, new therapeutic approaches before and after surgery, and what these developments mean for the future of melanoma care.